Breaking News, Collaborations & Alliances

Compugen Eligible for $7.5M AstraZeneca Milestone in Antibody Alliance

AstraZeneca doses first patient in its ARTEMIDE Phase 2 study with AZD2936, a PD-1/TIGIT bispecific antibody targeting tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, expects to receive a $7.5 million milestone payment from AstraZeneca, after AstraZeneca dosed the first patient in its ARTEMIDE Phase 2 study with AZD2936, a PD-1/TIGIT bispecific antibody derived from COM902, Compugen’s clinical-stage anti-TIGIT antibody.   “The advancement of AZD2936 into Phase 2 by AstraZeneca, a global leader in the development of oncology therapeutics,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters